Cytokinetics presents SEQUOIA-HCM baseline data: 282 patients enrolled, results due by end 2023

CYTOKINETICS INC

SEQUOIA-HCM enrolled 282 patients with symptomatic obstructive HCM; one third from US, half from Europe/Israel, remainder from China.
Mean age 59.1 years, 40.4% female, 78.7% white; baseline NYHA class II 75.9%, III 23.8%, IV 0.4%.
Background therapy: beta-blockers 61%, calcium channel blockers 26.6%, disopyramide 12.8%.
Key blinded baseline data include LVEF, LVOT gradients, and NT-proBNP; top-line results still expected by end of 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.